A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2002
11/21/2002	WO2002092016A2 Therapeutic use of rank antagonists
11/21/2002	WO2002092015A2 Reagents and methods for modulating dkk-mediated interactions
11/21/2002	WO2002092014A2 Destruction of prions using vibriolysin or variants thereof
11/21/2002	WO2002092013A2 Methods for treating liver disease and liver damage with growth hormone and foxm1b
11/21/2002	WO2002092008A2 Use of il-18 inhibitors for the treatement or prevention of sepsis
11/21/2002	WO2002092004A2 Use of hmg fragment as anti-inflammatory agents
11/21/2002	WO2002092001A2 Compositions and methods for the therapy and diagnosis of lung cancer
11/21/2002	WO2002092000A2 Hbm variants that modulate bone mass and lipid levels
11/21/2002	WO2002091999A2 Treatment for wounds
11/21/2002	WO2002091996A2 Methods for treating cancer
11/21/2002	WO2002091995A2 Method to induce neovascular formation and tissue regeneration
11/21/2002	WO2002091992A2 Targeted delivery of drugs for the treatment of parasitic infections
11/21/2002	WO2002091989A2 Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
11/21/2002	WO2002091969A1 Treating epidermlyosis bullosa with thymosin beta 4
11/21/2002	WO2002074981A3 Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
11/21/2002	WO2002074907A3 Methods of modulating surfactant production
11/21/2002	WO2002074784A3 Novel use of a peptide class of compound for treating non neuropathic inflammatory pain
11/21/2002	WO2002074322A3 Human growth hormone for treating children with abnormal short stature and kits and methods for diagnosing gs protein dysfunctions
11/21/2002	WO2002072137A3 Anaesthetic formulation comprising articaine
11/21/2002	WO2002069896A3 Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation
11/21/2002	WO2002066068A3 Method of treating neurological diseases
11/21/2002	WO2002064108A3 Delivery of biologically active agents
11/21/2002	WO2002063308A3 Prediction of wound healing by urinary nitrate assay
11/21/2002	WO2002062317A3 Bimodal dry powder formulation for inhalation
11/21/2002	WO2002059604A8 Diagnosis and treatment of multiple sclerosis
11/21/2002	WO2002058674A3 Process for preparing particles
11/21/2002	WO2002057779A9 Cloning and expression of a new mcp receptor in glial cells
11/21/2002	WO2002057290A3 Novel fibronectin epitopes and proteinaceous molecules capable of binding said epitopes
11/21/2002	WO2002056901A3 Cosmetic or pharmaceutical preparations of the treatment of epithelial outer tissue
11/21/2002	WO2002055712A3 Regulation of human alanine aminotransferase
11/21/2002	WO2002055098A3 Latency associated peptide for providing latency to pharmaceutically active proteins
11/21/2002	WO2002046402A3 Regulation of human patched-like protein
11/21/2002	WO2002044351A3 Regulation of human fatty acid coa ligase
11/21/2002	WO2002043785A3 Intraocular implants for preventing transplant rejection in the eye
11/21/2002	WO2002040536A3 Acylated antimicrobial peptides
11/21/2002	WO2002036171A9 Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
11/21/2002	WO2002022169A3 VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS
11/21/2002	WO2002020091A3 Antithrombotic compositions
11/21/2002	WO2002018637A3 Diagnosis and treatment of prostate cancer
11/21/2002	WO2002018341A9 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors
11/21/2002	WO2002008392A3 Regulation of human matriptase-like serine protease
11/21/2002	WO2001094383A3 Mutated furin polypeptides having improved characteristics
11/21/2002	WO2001080876A8 Utilization of adamts-1 protein and method of screening aggrecanase activity regulator
11/21/2002	WO2001036475A9 Biglycan and related therapeutics and methods of use
11/21/2002	WO2001034646A9 Recombinant gelatins
11/21/2002	WO2001025465A9 Adeno-associated viruses and uses thereof
11/21/2002	WO2001019397A9 Methods and compositions utilizing rad51
11/21/2002	WO2001017559A9 Semaphorin modulation of immune cell migration
11/21/2002	US20020174450 Transgenic mice containing cash gene disruptions
11/21/2002	US20020174448 Transgenic expression from a SOCS-3 promoter in vertebrate cells
11/21/2002	US20020174446 Identification of genes involved in alzheimer's disease using drosophila melanogaster
11/21/2002	US20020173851 Intervertebral disc treatment devices and methods
11/21/2002	US20020173643 Fusion protein delivery system and uses thereof
11/21/2002	US20020173642 Human gastric cancer antigen gene and gastric cancer antigen protein
11/21/2002	US20020173641 Nucleotide sequences coding polypeptides for use in human therapeutics, pharmacology and diagnostics
11/21/2002	US20020173640 Nucleotide sequences coding plypeptide for use in the treatment of tumors
11/21/2002	US20020173638 Nucleotide sequences coding polypeptide for use in the treatment, diagnosis and prevention of ovarian cancer
11/21/2002	US20020173629 Antibody for use in the treatment of cancer
11/21/2002	US20020173628 Chimeric IL-10 proteins and uses thereof
11/21/2002	US20020173625 Hybrid polypeptide for use in the treatment and prevention of allergic disorders
11/21/2002	US20020173624 Polypeptide for use in treatment and prevention of liver, nervous system and glandular disorders
11/21/2002	US20020173620 Bifunctional fusion proteins formed from hirudin and TAP
11/21/2002	US20020173586 Thermogelling biodegradable aqueous polymer solution
11/21/2002	US20020173549 Compositions and methods for treatment of mild cognitive impairment
11/21/2002	US20020173546 Composition of biochemical compounds involved in bioenergy metabolism of cells and method of use
11/21/2002	US20020173511 Serotonergic compositions and methods for treatment of mild cognitive impairment
11/21/2002	US20020173510 Nutrient mixture; fatty acid, calcium compound and vitamins
11/21/2002	US20020173504 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds
11/21/2002	US20020173488 Boronic Ester and acid compounds, synthesis and uses
11/21/2002	US20020173479 Administering genes to suppress cancer
11/21/2002	US20020173478 Controlling, prevention gene expression
11/21/2002	US20020173476 Cancer diagnosis
11/21/2002	US20020173475 Methods to inhibit viral replication
11/21/2002	US20020173474 Methods & materials involving dimerization-mediated regulation of biological events
11/21/2002	US20020173468 Modified cytostatic agents
11/21/2002	US20020173467 Peptide in biopolymer; oil in water emulsion
11/21/2002	US20020173465 Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
11/21/2002	US20020173464 Modulation of pericyte proliferation
11/21/2002	US20020173463 Isolated nucleic acids; and antibodies
11/21/2002	US20020173462 Fibrinogen binding protein
11/21/2002	US20020173461 Methods for enhancing the efficacy of cancer therapy
11/21/2002	US20020173460 Complexing with fibronectins; analyzing, calibration; antiinflammatory agents, respiratory system disorders
11/21/2002	US20020173459 Isolated peptide; antibodies; genetic engineering
11/21/2002	US20020173458 Polypeptides; genetic engineering
11/21/2002	US20020173457 Polypeptides
11/21/2002	US20020173456 Complex of macromolecules and peptide; supplying cells
11/21/2002	US20020173454 Nucleic acids, proteins, and antibodies
11/21/2002	US20020173453 Administering mammals a bone morphogenic protein, transforming growth factor, fibroblast growth factor
11/21/2002	US20020173452 Cytostatic-glycoconjugates having specifically cleavable linking units
11/21/2002	US20020173449 O-superfamily conotoxin peptides
11/21/2002	US20020173448 Method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5
11/21/2002	US20020173049 Controlling protein levels in eucaryotic organisms
11/21/2002	US20020173031 Amplification or reduction of drug resistance in bacteria, yeast, plant of mamalian cells; obtain cell, adjust adenosine triphosphate gradient, monitor drug resistance
11/21/2002	US20020173028 Nucleotide sequences coding polypeptide for use in the treatment and prevention of leukemia, cancer and blood disorders
11/21/2002	US20020173026 Survivin-interacting proteins and use thereof
11/21/2002	US20020173025 Human DNase I hyperactive variants
11/21/2002	US20020173022 Polypeptide for use in the diagnosis, prevention and treatment of inflammation and disorders associated with cell proliferation and apoptosis
11/21/2002	US20020173020 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of cell proliferation disorders
11/21/2002	US20020173018 Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
11/21/2002	US20020173007 Human chemokine polypeptides

1 ... 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 ... 3163